Generic drug copying reduces U.S. pharma profitability, Steve Hou notes

Generic drug copying reduces U.S. pharma profitability, Steve Hou notes
U.S. pharma faces generics and global rivals

Steve Hou draws a parallel between the U.S. pharmaceutical industry and the growth of generic drugs, highlighting the impact of generics and global competitors on innovation.

He argues that while U.S. pharma companies drive innovation, the rest of the world and generic manufacturers replicate these advances, ultimately eroding profitability and lowering incentives to innovate. Hou also notes that factors like collective bargaining have yet to be fully addressed in this context, adding to industry challenges.

Hou has commented on sector dynamics in prior market updates. He recently observed that Intel's EMIB advanced packaging technology remains relevant despite recent Intel performance since February. In another report, he acknowledged positive moves for HOOD and TER and noted challenges facing KTOS investors in the market.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.